搜索筛选:
搜索耗时2.7681秒,为你在为你在102,285,761篇论文里面共找到 4 篇相符的论文内容
发布年度:
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase Ⅱ study of FOLFOX6 plus panitumumab (pma
[会议论文] 作者：Hua Yu,Kelly S.Oliner,William Y.Go,Lee Schwartzberg,Fernando Rivera,Meinolf Karthaus,Gianpiero Fasola,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
...
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase Ⅱ study of FOLFOX6 plus panitumumab (pma
[会议论文] 作者：Lee Schwartzberg,Fernando Rivera,Meinolf Karthaus,Gianpiero Fasola,Jean-Luc Canon,Hua Yu,Kelly S.Oliner,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
目的: PEAK estimated the tx effect of FOLFOX6 with pmab or bev in 1st-line WT KRAS mCRC.The PRIME study showed significantly improved progression free survival (PFS) and overall survival (OS) with pmab+...
Analysis of KRAS/NRAS and BRAF Mutations in the Phase 3 PRIME Study of Panitumumab+FOLFOX4 vs.FOLFOX
[会议论文] 作者：Tabernero,Ronald Burkes,Mario Barugel,Yves Humblet,Gyorgy Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
Background: Analysis of a phase 3 panitumumab monotherapy study suggested that KRAS and NRAS mutations beyond KRAS exon 2 may be predictive of panitumumab efficacy (Peeters M,et al.Clin Cancer Res 201...
[会议论文] 作者：Tabernero,Ronald Burkes,Mario Barugel,Yves Humblet,Gyorgy Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
目的: The primary and final analyses of PRIME demonstrated that panitumumab+FOLFOX4 significantly improved progression-free survival (PFS) vs.FOLFOX4 alone for 1st-line treatment of patients with wild-t...
相关搜索：
